慢性乙型肝炎基层诊疗指南(2020年)

2021-02-20 中华医学会 中华全科医师杂志.2021.20(2):137-149.

本指南适用于基层,旨在帮助全科医生,在CHB的预防、筛查、诊断、治疗和长期随访管理中做出合理决策,但不是强制性标准,也不可能包括或解决CHB管理的所有问题。因此,全科医生在诊治CHB患者时,应在充分了

中文标题:

慢性乙型肝炎基层诊疗指南(2020年)

发布机构:

中华医学会

发布日期:

2021-02-20

简要介绍:

本指南适用于基层,旨在帮助全科医生,在CHB的预防、筛查、诊断、治疗和长期随访管理中做出合理决策,但不是强制性标准,也不可能包括或解决CHB管理的所有问题。因此,全科医生在诊治CHB患者时,应在充分了解有关本病的最佳临床证据、认真考虑患者具体病情和意愿的基础上,根据自己的专业知识、临床经验和可利用的医疗资源,制定全面合理的诊疗方案。我们将根据国内外的有关进展情况,继续对本指南进行不断更新和完善。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=慢性乙型肝炎基层诊疗指南(2020年).pdf)] GetToolGuiderByIdResponse(projectId=1, id=84c421c002083a02, title=慢性乙型肝炎基层诊疗指南(2020年), enTitle=, guiderFrom=中华全科医师杂志.2021.20(2):137-149., authorId=0, author=, summary=本指南适用于基层,旨在帮助全科医生,在CHB的预防、筛查、诊断、治疗和长期随访管理中做出合理决策,但不是强制性标准,也不可能包括或解决CHB管理的所有问题。因此,全科医生在诊治CHB患者时,应在充分了, cover=https://img.medsci.cn/2021420/1618929382150_2020535.jpg, journalId=0, articlesId=null, associationId=359, associationName=中华医学会, associationIntro=中华医学会是中国医学科学技术工作者自愿组成并依法登记成立的学术性、公益性、非营利性法人社团,是党和国家联系医学科技工作者的桥梁和纽带,是发展中国医学科学技术事业的重要社会力量。 中华医学会(Chinese Medical Association)成立于1915年。现有83个专科分会,50万名会员,下设部门16个,法人实体机构3个,另与解放军军事医学科学院合办医学图书馆1个。 中华医学会的主要业务包括:开展医学学术交流;编辑出版123种医学、科普等各类期刊及100余种音像出版物;开展继续医学教育;开展国际间学术交流;开展医学科技项目的评价、评审和医学科学技术决策论证;评选和奖励优秀医学科技成果(包括学术论文和科普作品等);开展专科医师的培训和考核;发现、推荐和培养优秀医学科技人才;宣传、奖励医德高尚、业务精良的医务人员;承担政府委托职能及承办委托任务;设立临床研究专项资金,提高临床科研水平;组织医疗事故技术鉴定和预防接种异常反应技术鉴定工作;推动医学科研成果的转化和应用;向党和政府反映医学科技工作者的意见和要求。, copyright=0, guiderPublishedTime=Sat Feb 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本指南适用于基层,旨在帮助全科医生,在CHB的预防、筛查、诊断、治疗和长期随访管理中做出合理决策,但不是强制性标准,也不可能包括或解决CHB管理的所有问题。因此,全科医生在诊治CHB患者时,应在充分了解有关本病的最佳临床证据、认真考虑患者具体病情和意愿的基础上,根据自己的专业知识、临床经验和可利用的医疗资源,制定全面合理的诊疗方案。我们将根据国内外的有关进展情况,继续对本指南进行不断更新和完善。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2629, tagName=慢性乙型肝炎)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20369, categoryName=向日葵, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2629, guiderKeyword=慢性乙型肝炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=24042, appHits=432, showAppHits=0, pcHits=1521, showPcHits=23609, likes=2, shares=56, comments=13, approvalStatus=1, publishedTime=Tue Apr 20 23:14:38 CST 2021, publishedTimeString=2021-02-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Apr 20 22:36:30 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Wed Jan 03 08:39:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=慢性乙型肝炎基层诊疗指南(2020年).pdf)])
慢性乙型肝炎基层诊疗指南(2020年).pdf
下载请点击:
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2113322, encodeId=1d9521133223a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210412/ed7fbddfbc0d4a75affee17ba0f2528c/7a517c94ffa54cf99af33647f3fe9aa5.jpg, createdBy=528b5420040, createdName=SunshineR吖呀, createdTime=Mon Feb 06 23:24:40 CST 2023, time=2023-02-06, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1211859, encodeId=d82d12118592d, content=很很实用,谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15705834, createdName=ms4000001809038213, createdTime=Sun Apr 17 12:07:25 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200591, encodeId=fca01200591b9, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Tue Mar 08 16:08:38 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077756, encodeId=735010e775688, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f5470347, createdName=ms9000000147769830, createdTime=Tue Dec 07 15:10:43 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004365, encodeId=e70b10043654d, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c5415602, createdName=ms5000001065048298, createdTime=Sun Aug 01 10:24:20 CST 2021, time=2021-08-01, status=1, ipAttribution=)]
    2023-02-06 SunshineR吖呀 来自福建省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2113322, encodeId=1d9521133223a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210412/ed7fbddfbc0d4a75affee17ba0f2528c/7a517c94ffa54cf99af33647f3fe9aa5.jpg, createdBy=528b5420040, createdName=SunshineR吖呀, createdTime=Mon Feb 06 23:24:40 CST 2023, time=2023-02-06, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1211859, encodeId=d82d12118592d, content=很很实用,谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15705834, createdName=ms4000001809038213, createdTime=Sun Apr 17 12:07:25 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200591, encodeId=fca01200591b9, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Tue Mar 08 16:08:38 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077756, encodeId=735010e775688, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f5470347, createdName=ms9000000147769830, createdTime=Tue Dec 07 15:10:43 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004365, encodeId=e70b10043654d, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c5415602, createdName=ms5000001065048298, createdTime=Sun Aug 01 10:24:20 CST 2021, time=2021-08-01, status=1, ipAttribution=)]
    2022-04-17 ms4000001809038213

    很很实用,谢谢!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2113322, encodeId=1d9521133223a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210412/ed7fbddfbc0d4a75affee17ba0f2528c/7a517c94ffa54cf99af33647f3fe9aa5.jpg, createdBy=528b5420040, createdName=SunshineR吖呀, createdTime=Mon Feb 06 23:24:40 CST 2023, time=2023-02-06, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1211859, encodeId=d82d12118592d, content=很很实用,谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15705834, createdName=ms4000001809038213, createdTime=Sun Apr 17 12:07:25 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200591, encodeId=fca01200591b9, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Tue Mar 08 16:08:38 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077756, encodeId=735010e775688, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f5470347, createdName=ms9000000147769830, createdTime=Tue Dec 07 15:10:43 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004365, encodeId=e70b10043654d, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c5415602, createdName=ms5000001065048298, createdTime=Sun Aug 01 10:24:20 CST 2021, time=2021-08-01, status=1, ipAttribution=)]
    2022-03-08 gghhzb

    很实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2113322, encodeId=1d9521133223a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210412/ed7fbddfbc0d4a75affee17ba0f2528c/7a517c94ffa54cf99af33647f3fe9aa5.jpg, createdBy=528b5420040, createdName=SunshineR吖呀, createdTime=Mon Feb 06 23:24:40 CST 2023, time=2023-02-06, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1211859, encodeId=d82d12118592d, content=很很实用,谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15705834, createdName=ms4000001809038213, createdTime=Sun Apr 17 12:07:25 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200591, encodeId=fca01200591b9, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Tue Mar 08 16:08:38 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077756, encodeId=735010e775688, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f5470347, createdName=ms9000000147769830, createdTime=Tue Dec 07 15:10:43 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004365, encodeId=e70b10043654d, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c5415602, createdName=ms5000001065048298, createdTime=Sun Aug 01 10:24:20 CST 2021, time=2021-08-01, status=1, ipAttribution=)]
    2021-12-07 ms9000000147769830

    可以的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2113322, encodeId=1d9521133223a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210412/ed7fbddfbc0d4a75affee17ba0f2528c/7a517c94ffa54cf99af33647f3fe9aa5.jpg, createdBy=528b5420040, createdName=SunshineR吖呀, createdTime=Mon Feb 06 23:24:40 CST 2023, time=2023-02-06, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1211859, encodeId=d82d12118592d, content=很很实用,谢谢!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15705834, createdName=ms4000001809038213, createdTime=Sun Apr 17 12:07:25 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200591, encodeId=fca01200591b9, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d852717242, createdName=gghhzb, createdTime=Tue Mar 08 16:08:38 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077756, encodeId=735010e775688, content=可以的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f5470347, createdName=ms9000000147769830, createdTime=Tue Dec 07 15:10:43 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004365, encodeId=e70b10043654d, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7c5415602, createdName=ms5000001065048298, createdTime=Sun Aug 01 10:24:20 CST 2021, time=2021-08-01, status=1, ipAttribution=)]
    2021-08-01 ms5000001065048298

    有用

    0

拓展阅读

美国慢性乙型肝炎感染的治疗规范:2015年更新版

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2016-06-02

2015 中国慢性乙型肝炎防治指南—— 特殊人群抗病毒治疗推荐意见解读

中华医学会肝病学分会(Chinese Society of Hepatology, CMA) · 2015-03-11

2015 中国慢性乙型肝炎防治指南解读

中华医学会肝病学分会(Chinese Society of Hepatology, CMA) · 2016-03-10

聚乙二醇干扰素α治疗慢性乙型肝炎专家共识

中国肝病科相关专家小组(统称) · 2017-09-30